Intensive studies has been focused on the use of non-insulin anti-hyperglycaemic agents, including agonists of glucagon-like peptide-1 receptor (GLP-1R) and inhibitors of sodium-glucose co-transporter-2 (SGLT-2), in the treatments of T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.